ÄãºÃ£¬»¶Ó­À´µ½¾­¹ÜÖ®¼Ò [µÇ¼] [×¢²á]

ÉèΪÊ×Ò³ | ¾­¹ÜÖ®¼ÒÊ×Ò³ | Êղر¾Õ¾

ËûÍ¡ÀàÒ©Îï¶ÔÉñ¾­Ï¸°ûºÍÉñ¾­½ºÖÊϸ°ûABCA1»ùÒò±í´ïµÄÓ°Ïì_ҩѧרҵ±ÏÒµÂÛÎÄ·¶ÎÄ

·¢²¼Ê±¼ä£º2014-12-23 À´Ô´£ºÈË´ó¾­¼ÃÂÛ̳
ËûÍ¡ÀàÒ©Îï¶ÔÉñ¾­Ï¸°ûºÍÉñ¾­½ºÖÊϸ°ûABCA1»ùÒò±í´ïµÄÓ°Ïì_ҩѧרҵ±ÏÒµÂÛÎÄ·¶ÎÄ ¡¾ÕªÒª¡¿  Ä¿µÄ ¹Û²ìËûÍ¡ÀàÒ©Îï¶ÔÉñ¾­Ï¸°ûºÍÉñ¾­½ºÖÊϸ°ûATP½áºÏºÐʽתÔËÌå1(ATPª²binding cassette transporter 1, ABCA1)»ùÒò±í´ïµÄÓ°Ïì¡£·½·¨ ÅàÑøÈËÀàÉñ¾­Ï¸°ûºÍÉñ¾­½ºÖÊϸ°û£¬·Ö±ð¼ÓÈ벻ͬŨ¶ÈµÄÐÁ·¥ËûÍ¡(simvastatin)ºÍÆÕ·¥ËûÍ¡(pravastatin)£¬·õÓý²»Í¬Ê±¼äºó·Ö±ðÌáȡϸ°û×ÜRNAºÍ°ûÖʵ°°×£¬RTª²PCR¹Û²ìABCA1»ùÒòµÄ±í´ï£¬Western blot¼ì²âABCA1µ°°×¡£½á¹û ÐÁ·¥ËûÍ¡ºÍÆÕ·¥ËûÍ¡×éÏÔÖø½µµÍÁËABCA1»ùÒòºÍµ°°×µÄ±í´ï£¬ÆäÖÐÐÁ·¥ËûÍ¡µÄ×÷ÓñÈÆÕ·¥ËûÍ¡Ã÷ÏÔ(ÐÁ·¥ËûÍ¡¶ÔÉñ¾­ÔªºÍÉñ¾­½ºÖÊϸ°ûABCA1»ùÒò±í´ï·Ö±ð½µµÍ95%ºÍ75%P0.05)£¬Éñ¾­ÔªÊµÑé×é±ÈÉñ¾­½ºÖÊϸ°û×é¸üΪÃô¸Ð¡£½áÂÛ ËûÍ¡ÀàÒ©Îï¿ÉÒÔÏÔÖø½µµÍÉñ¾­ÔªºÍÉñ¾­½ºÖÊϸ°ûABCA1»ùÒòºÍµ°°×µÄ±í´ï£¬ABCA1µÄ½µµÍÓпÉÄÜÓ°Ïìϸ°ûÄÚµ¨¹Ì´¼µÄ´úл£¬¶ÔÈ«ÃæÆÀ¼ÛËûÍ¡ÀàÒ©Îï¶Ô¸ßѪ֬Ïà¹Ø»ùÒòµÄÓ°Ïì¼°ÓÃÒ©°²È«ÐÔÌṩÁËÒ»¶¨µÄʵÑéÒÀ¾Ý¡£ ¡¾¹Ø¼ü´Ê¡¿  ATP½áºÏºÐʽתÔËÌå1;ÐÁ·¥ËûÍ¡;ÆÕ·¥ËûÍ¡ ABSTRACT: Objective To observe the effects of statins on ATPª²binding cassette transporter 1 (ABCA1) gene expression in neurons and astrocytes.Methods Primary human astrocytes and neuron cell line HCNª²2 were incubated with simvastatin and pravastatin at different concentrations and under different conditions. Using RNA isolated from the cultured cells, we performed quantitative PCR to measure the ABCA1 gene expression in astrocytes and neurons. The protein expression of ABCA1 was measured by Western blot.Results The two statins significantly decreased the ABCA1 gene and protein expressions. Compared with pravastatin, simvastatin significantly reduced the expression of ABCA1 in neurons and astrocytes by 95% and 75%, respectively (both P0.05). The neurons were more sensitive than astrocytes.Conclusion The statins are capable of decreasing the ABCA1 gene and protein expressions in neurons and astrocytes, and decreased ABCA1 expression may affect cholesterol metabolism in cells. The results may provide an important experimental basis for comprehensive evaluation of the statins to treat hyperlipidemia. KEY WORDS: ATPª²binding cassette transporter 1 (ABCA1); simvastatin; pravastatin ËûÍ¡ÀàÒ©ÎïÊÇÁÙ´²³£ÓõÄÒ»ÀཱུѪ֬ҩÎï[1ª²2]£¬ÆäÖ÷Òª³É·ÖΪµ¨¹Ì´¼ºÏ³ÉÏÞËÙøôǼ×Îì¶þõ£¸¨Ã¸A(HMGª²CoA)»¹Ô­Ã¸µÄÒÖÖƼÁ¡£ÐÁ·¥ËûÍ¡(simvastatin)ºÍÆÕ·¥ËûÍ¡(pravastatin)Òѹ㷺ӦÓÃÓÚ¸ßѪ֢֬µÄÁÙ´²ÖÎÁÆ¡£ÓÉÓÚ¸ÃÒ©×è¶Ï¼×ôÇÎìËáµÄÉú»¯Í¾¾¶£¬²»µ«ÄÜÒÖÖƵ¨¹Ì´¼µÄºÏ³É¡¢½µµÍѪ½¬LDLµÄˮƽ¡¢×èÖ¹¾ÞÊÉϸ°ûÏòÅÝĭϸ°ûµÄת»¯£¬¶øÇÒ¿ÉÒÔÏÔÖø½µµÍÒò¸ßѪ֬ÒýÆðµÄ¶¯ÂöÖàÑùÓ²»¯ÐÔ¼²²¡µÄËÀÍöÂÊ[3]¡£´ËÍ⣬Ñо¿±íÃ÷£¬ËûÍ¡ÀàÒ©Îﻹ¿ÉÒÔÉý¸ßѪ½¬¸ßÃܶÈÖ¬µ°°× (high density lipoprotein, HDL)ºÍÔØÖ¬µ°°×A¡£ ATP½áºÏºÐʽתÔËÌå1(ATPª²binding cassette transporter 1, ABCA1)ÊÇATP½áºÏºÐʽתÔ˵°°×Ö®Ò»£¬ËüÒÔATPΪÄÜÔ´£¬´Ù½øϸ°ûÄÚÓÎÀ뵨¹Ì´¼ºÍÁ×Ö¬µÄÁ÷³ö£¬ÔÚµ¨¹Ì´¼ÄæתÔË(RCT)ºÍHDLÉú³ÉµÄÆðʼ²½ÖèÖÐÆðÖØÒª×÷Óá£ABCA1»ùÒò´íÒåÍ»±äËùÒýÆðµÄÔÓºÏ×ÓÐÍTangier¼²²¡£¬¾ÍÊÇÓÉÓÚapoA IËù½éµ¼µÄµ¨¹Ì´¼Á÷³ö¼õÉÙ¡¢HDLª²CŨ¶È½µµÍºÍ¿ÅÁ£Ö±¾¶±äС¶øÔì³É[4]¡£×÷ΪDZÔڵĿ¹ÖàÑùÓ²»¯µÄ°ÐµãÖ®Ò»£¬Éϵ÷ABCA1»ùÒòµÄ±í´ï¾ßÓÐÖØÒªÒâÒå¡£apoA IÊÇHDLÖÐÖ÷ÒªµÄµ°°×ÖÊ£¬ÊÇϸ°ûµ¨¹Ì´¼ÄæÏòתÔ˵ÄÌØÊâÖØÒªÒòËØ¡£apoA IÄÜÓëÁ×Ö¬¡¢¶àÖÖѪ½¬Òò×Ó¼°Ï¸°ûĤÊÜÌå½áºÏ, ¿ÉÒÔ¼¤»îÂÑÁ×Ö¬µ¨¹Ì´¼õ£»ùתÒÆø(LCAT)£¬Æð×Å´Ù½øϸ°ûÄÚµ¨¹Ì´¼µÄÒƳö¡¢õ¥»¯¡¢×ªÒÆ¡¢ÒÔ¼°µ÷½ÚHDL´úлµÄ×÷ÓÃ[5]¡£ ÒÔÍùѧÕßÈÏΪ£¬ËûÍ¡ÀàÒ©Îï¿ÉÄܶÔÀÏÄê³Õ´ôÖ¢ÓÐÒ»¶¨µÄÔ¤·À×÷ÓÃ[6]¡£µ«ÊÇ£¬½üÄêÀ´ÓйØËûÍ¡ÀàÒ©Îï¿ÉÄܵ¼ÖÂÀÏÄê³Õ´ôÖ¢»òÕß¼ÓÖØÔ­ÓÐÖ¢×´µÄ±¨µÀÔ½À´Ô½¶à[7ª²9]¡£Ä¿Ç°£¬ÓйØËûÍ¡ÀàÒ©Îï¶ÔÖÐÊàÉñ¾­ÏµÍ³ABCA1»ùÒòµÄÓ°Ï컹δ¼û±¨µÀ¡£±¾ÊµÑéͨ¹ý¹Û²ìÐÁ·¥ËûÍ¡¡¢ÆÕ·¥ËûÍ¡¶ÔÕý³£Éñ¾­Ï¸°ûºÍÉñ¾­½ºÖÊϸ°ûÖÐABCA1»ùÒò±í´ïµÄÓ°Ï죬³õ²½½âÊÍÁËËûÍ¡ÀàÒ©ÎïÓпÉÄÜÔì³É»¼ÕßÀÏÄê³Õ´ôÖ¢µÄ·¢Éú»òÕßÖ¢×´¼ÓÖصÄÔ­Òò£¬Îª½øÒ»²½½ÒʾËûÍ¡ÀàÒ©ÎïµÄ×÷ÓûúÖƼ°ÆäÓëÉñ¾­ÏµÍ³ÍËÐÐÐÔ¼²²¡µÄ¹Øϵ´òÏÂÒ»¶¨µÄ»ù´¡¡£ 1 ²ÄÁÏÓë·½·¨ 1.1 ²ÄÁÏ Éñ¾­Ï¸°ûϵHCNª²2(CRLª²10742)¹º×ÔÃÀ¹úATCC¹«Ë¾£¬Éñ¾­½ºÖÊϸ°ûϵΪ±¾ÊµÑéÊÒ±£´æ¡£ÐÁ·¥ËûÍ¡¡¢ÆÕ·¥ËûÍ¡¡¢¼×ôÇÎìËá¡¢FPPºÍGGPP¾ù¹º×ÔSIGMA¹«Ë¾¡£RNAÌáÈ¡ÊÔ¼ÁºÐ¹º×ÔÃÀ¹úQIAGEN¹«Ë¾¡£Memª²PERÕæºËϸ°ûĤµ°°×ÌáÈ¡ÊÔ¼ÁºÐ¹º×ÔÃÀ¹úPierce¹«Ë¾¡£ 1.2 ·½·¨ 1.2.1 ϸ°ûÅàÑø ³£¹æÅàÑøÉñ¾­ÔªºÍÉñ¾­½ºÖÊϸ°û£¬
¾­¹ÜÖ®¼Ò¡°Ñ§µÀ»á¡±Ð¡³ÌÐò
  • ɨÂë¼ÓÈë¡°¿¼ÑÐѧϰ±Ê¼ÇȺ¡±
ÍƼöÔĶÁ
¾­¼ÃѧÏà¹ØÎÄÕÂ
±êÇ©ÔÆ
¾­¹ÜÖ®¼Ò¾«²ÊÎÄÕÂÍƼö